Rezolute Completes Phase 3 upLIFT Trial Enrollment for Ersodetug
Rezolute, Inc. (RZLT) has completed patient enrollment in its Phase 3 upLIFT study evaluating ersodetug for the treatment of tumor hyperinsulinism. The late-stage trial finished recruiting with 16 participants in its single-arm, open-label study.
The trial measures whether ersodetug can produce at least a 50% reduction in glucose infusion rates, with success defined by a responder rate whose confidence interval lower bound reaches at least 30%. In preliminary data from the study, 7 of the first 8 enrolled patients successfully met this primary responder benchmark.
Investors and healthcare providers are now awaiting topline data from the trial, which the company expects to report in mid-December 2026. A favorable trial outcome could pave the way for regulatory steps in 2027. Shares of Rezolute, Inc. fell 7.27% to $4.275 following the announcement.
Key points
- Rezolute, Inc. fully enrolled 16 participants in its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism.
- Preliminary data showed 7 of the first 8 participants achieved the primary endpoint of a 50% or greater reduction in glucose infusion rate.
- Topline trial results from the single-arm, open-label study are expected in mid-December 2026.
- A successful readout could support potential regulatory progress in 2027.
- Rezolute stock fell 7.27% to $4.275 on the day of the announcement.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
When will Rezolute release Phase 3 upLIFT trial results for ersodetug?
Rezolute expects to release topline results for the Phase 3 upLIFT study in mid-December 2026.
What is the primary endpoint of the Phase 3 upLIFT study?
The primary endpoint is achieving a 50% or greater reduction in glucose infusion rate, with a responder rate whose confidence interval lower bound is at least 30%.
How many patients enrolled in the Phase 3 upLIFT study?
The Phase 3 upLIFT study fully enrolled a total of 16 participants.